You are here

CAR-T

CAR-T Cell Therapy Is Here To Stay

CAR-T Cell Therapy Is Here To Stay

Forbes

Flag link:

How Novartis' FDA Win In Cancer Also Could Be A Boon For Its Rivals

How Novartis' FDA Win In Cancer Also Could Be A Boon For Its Rivals

Investors Business Daily

Flag link:

Novartis wins unanimous support from FDA panel on groundbreaking CAR-T med

Novartis wins unanimous support from FDA panel on groundbreaking CAR-T med

Fierce Pharma

advisory panels

Flag link:

D-day: Novartis arrives at a crossroad in the blockbuster race to win the first FDA OK for CAR-T

D-day: Novartis arrives at a crossroad in the blockbuster race to win the first FDA OK for CAR-T

Endpoints

Flag link:

FDA panel to focus on safety of Novartis gene therapy drug

FDA panel to focus on safety of Novartis gene therapy drug

Yahoo/Reuters

advisory panels

acute lymphoblastic leukemia

Flag link:

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

Endpoints

Oxford BioMedica

Flag link:

Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?

Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?

Investors Business Daily

Juno Therapeutics

immuno-oncology

Flag link:

3 Top-Performing Biotech Stocks This Week

3 Top-Performing Biotech Stocks This Week

Motley Fool

Lexicon Pharmaceuticals

Flag link:

With Kite’s PDUFA date looming, federal court tosses Juno’s CAR-T patent challenge — for now

With Kite’s PDUFA date looming, federal court tosses Juno’s CAR-T patent challenge — for now

Endpoints

Juno Therapeutics

Flag link:

Kite Pharma: How High Will It Fly?

Kite Pharma: How High Will It Fly?

Seeking Alpha

Flag link:

Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment

Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment

Bloomberg

Flag link:

Novartis' CAR-T stacks up to Kite in lymphoma

Novartis' CAR-T stacks up to Kite in lymphoma

BioPharma Dive

Flag link:

ASCO17: Juno marks progress with second-gen CAR-T

ASCO17: Juno marks progress with second-gen CAR-T

BioPharma Dive

Juno Therapeutics

non-Hodgkin's lymphoma

Flag link:

July 12 FDA panel review looms as a watershed moment in Novartis’ campaign to win an historic new drug OK

July 12 FDA panel review looms as a watershed moment in Novartis’ campaign to win an historic new drug OK

Endpoints

advisory panels

pediatric B-cell acute lymphoblastic leukemia

Flag link:

ASCO dark horse Nanjing Legend Biotech shines with promising CAR-T data

ASCO dark horse Nanjing Legend Biotech shines with promising CAR-T data

Fierce Biotech

Nanjing Legend Biotech

Flag link:

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?

Endpoints

Multiple Myeloma

Flag link:

Kite Pharma's ASCO ads aim to prep docs on CAR-T ahead of FDA approval

Kite Pharma's ASCO ads aim to prep docs on CAR-T ahead of FDA approval

Fierce Pharma

Flag link:

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for

Endpoints

PDL-1 inhibitors

NewLink Genetics

Juno Therapeutics

Bristol-Myers Squibb

Flag link:

7 Areas to watch from the ASCO abstracts

7 Areas to watch from the ASCO abstracts

BioPharma Dive

NewLink Genetics

Juno Therapeutics

Flag link:

After Kite Pharma stuns analysts with news of a death in lead CAR-T study, safety questions sour launch forecast

After Kite Pharma stuns analysts with news of a death in lead CAR-T study, safety questions sour launch forecast

Endpoints

Flag link: